According to the 2025 WHO guidelines, what is the recommended 4‑month treatment regimen for drug‑susceptible pulmonary tuberculosis in patients aged ≥12 years (or ≥30 kg) without resistance to rifampin, isoniazid, fluoroquinolones, or pyrazinamide?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

WHO 4-Month TB Regimen for Drug-Susceptible Pulmonary Tuberculosis

For patients aged ≥12 years with drug-susceptible pulmonary TB, the 2025 ATS/CDC/ERS/IDSA guidelines strongly recommend a 4-month regimen consisting of rifapentine, moxifloxacin, isoniazid, and pyrazinamide (2HPMZ/2HPM) as an alternative to the standard 6-month regimen. 1

Regimen Structure

The 4-month treatment consists of:

Intensive Phase (8 weeks/56 doses):

  • Rifapentine: 1,200 mg daily
  • Moxifloxacin: 400 mg daily
  • Isoniazid: 300 mg daily (with pyridoxine 25-50 mg/day)
  • Pyrazinamide: Weight-based dosing
    • 40-<55 kg: 1,000 mg
    • 55-75 kg: 1,500 mg

    • 75 kg: 2,000 mg

Continuation Phase (9 weeks/63 doses):

  • Rifapentine: 1,200 mg daily
  • Moxifloxacin: 400 mg daily
  • Isoniazid: 300 mg daily (with pyridoxine)

Total: 119 doses administered 7 days/week with food, with at least 5 of 7 weekly doses under direct observation 2

Evidence Base

This recommendation is based on the Study 31/A5349 phase III trial, which demonstrated non-inferiority of the rifapentine-moxifloxacin regimen compared to standard 6-month therapy. The trial showed:

  • Cure rate: 84.6% vs 85.4% (risk difference -0.9%, 95% CI -4.3 to 2.6) 1
  • High certainty of evidence for cure outcomes 1
  • Similar adverse event rates: Grade 3+ adverse events occurred in 18.7% vs 19.3% 1
  • Non-inferior outcomes across multiple analyses 3

Patient Eligibility Criteria

Must Meet ALL of the Following:

  • Age ≥12 years AND body weight ≥40 kg 2
  • Pulmonary TB (not extrapulmonary forms requiring prolonged treatment)
  • Drug-susceptible organism confirmed or strongly suspected
  • No known resistance to rifampin, isoniazid, fluoroquinolones, or pyrazinamide
  • No contraindications to regimen components

Exclusions Requiring Clinical Consultation:

  • Recent TB treatment exposure: >5 doses of any TB drug (INH, rifamycins, PZA, fluoroquinolones) in preceding 30 days 2
  • Hepatic dysfunction: ALT/AST >3× upper limit normal, total bilirubin >2.5× upper limit normal, or advanced liver disease 2
  • Renal dysfunction: Creatinine >2× upper limit normal, renal insufficiency, or end-stage renal disease 2
  • Electrolyte abnormalities: Potassium <3.5 mEq/L 2
  • Severe extrapulmonary TB: CNS, bone/joint, miliary, or pericardial TB 1
  • HIV coinfection: Only eligible if CD4 ≥100 cells/μL and receiving/planning efavirenz-based ART without other drug-drug interactions 2

Critical Implementation Considerations

Fluoroquinolone-Related Adverse Events

Moxifloxacin carries specific risks that require patient counseling:

  • Neuropathy (peripheral and central)
  • Tendinitis and tendon rupture (especially in older adults, corticosteroid users)
  • QT prolongation (though routine ECG monitoring not required unless clinically indicated by age, cardiac history, or concurrent QT-prolonging medications) 1
  • Dysglycemia 1

Monitoring Requirements

  • Baseline: Sputum AFB smear and culture, molecular DST for INH/PZA/RIF/fluoroquinolones, phenotypic DST panel 2
  • Monthly: Respiratory specimens for AFB culture until two consecutive negatives 2
  • Clinical and laboratory assessments per protocol 2

Common Pitfalls to Avoid

  1. Do not use this regimen for smear-negative, culture-negative, noncavitary TB without careful consideration—while it may be used, the 2016 CDC 4-month regimen for paucibacillary disease exists as an alternative 2

  2. Do not assume eligibility without confirming drug susceptibility testing results—molecular testing should include at minimum rifampin, isoniazid, fluoroquinolones, and pyrazinamide 2

  3. Do not overlook drug-drug interactions in HIV-positive patients—only efavirenz-based ART is specifically studied with this regimen 2

  4. Do not use in children <12 years or <40 kg—for children 3 months to 16 years with nonsevere TB, the 2025 guidelines recommend a different 4-month regimen: 2HRZ(E)/2HR 1

Real-World Implementation Challenges

Recent data from NYC Health Department clinics revealed significant challenges: of 284 eligible patients, only 40 (14%) were prescribed the regimen, 36 initiated treatment, and merely 13 (36%) completed it, with 42% discontinuing due to adverse events 4. This underscores the importance of careful patient selection and close monitoring.

Alternative for Specific Populations

For children 3 months to 16 years with nonsevere TB: The 2025 guidelines provide a strong recommendation for 2HRZ(E)/2HR (2 months intensive phase, 2 months continuation phase) rather than the standard 6-month regimen, with moderate certainty of evidence 1

References

4
Research

Challenges to initiate and complete a 4-month rifapentine-moxifloxacin TB treatment regimen.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2025

Related Questions

What are the dosing and specifications for the 3HR (3‑month daily isoniazid plus rifampin) regimen in a non‑pregnant adult with latent Mycobacterium tuberculosis infection and no known drug resistance?
How should an anti‑tuberculosis (ATT) overdose be managed?
Could a patient on four‑month isoniazid‑rifampicin therapy, also receiving apixaban and ivabradine, presenting with fever and vomiting have concomitant pneumonia?
Can tuberculosis be diagnosed with a chest X‑ray alone?
What is the recommended 3HR (isoniazid and rifampicin) regimen according to the National Tuberculosis Elimination Programme (NTEP) for tuberculosis preventive therapy?
For a male patient on Lexapro (escitalopram) 5 mg daily for 4 weeks with improved mood but erectile dysfunction, should I augment therapy or switch to another antidepressant?
In a 50‑year‑old female with type 2 diabetes mellitus and hyperlipidaemia on semaglutide (Ozempic) and high‑intensity atorvastatin 80 mg, with triglycerides of 441 mg/dL and total cholesterol of 163 mg/dL, what treatment should be initiated to lower the triglyceride level?
What does a low Depakote (valproic acid) level indicate?
Based on the BAARS‑IV scores (current ADHD total score 36, borderline‑to‑mild; childhood combined score 47, moderate‑to‑severe) and reported functional impairment in school, home, work, and social settings, does this adult meet criteria for Attention‑Deficit/Hyperactivity Disorder, combined type, and what pharmacologic and non‑pharmacologic treatment should be initiated?
What is bilastine (second‑generation H1‑receptor antagonist)?
Can a patient allergic to gabapentin safely take Lyrica (pregabalin)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.